PathAI has launched a new digital pathology platform, AISight. Supporting AI-driven research, the digital pathology platform was trained on a real-world dataset of over 5,000 samples with inputs from more than 350,000 cell and tissue-level annotations from more than 50 pathologists. The company has also released its AIM-PD-L1 NSCLC RUO algorithm, which calculates the percentage of PD-L1 positive tumor and immune cells in NSCLC samples. The AIM-PD-L1 NSCLC RUO algorithm calculates the percentage of PD-L1 positive tumor and immune cells in NSCLC samples over the entire slide image (WSI).
Validating the AIM-PD-L1 NSCLC algorithm
PathAI previously shared validation data for the AIM-PD-L1 NSCLC algorithm at the AACR Annual Meeting in 2022. The AISight Early Access Network laboratories will build on this work by testing the algorithm’s performance on real-world data. Other IHC quantitation algorithms for various types of cancer are also available to these labs. PathAI previously published data in Modern Pathology indicating that AI-powered PD-L1 algorithms have the potential to identify more patients who would benefit from immuno-oncology therapy than current manual assessment guidelines. Late last year, the company also shared findings on the use of machine learning (ML) to enhance the scoring of nonalcoholic steatohepatitis (NASH) at the 2022 AASLD 2022 Liver Meeting. The digital pathology platform company expects its new tools to aid AI-driven research and provide a more precise understanding of the immune response in NSCLC. As a result, the new offerings are relevant to the advancement of precision medicine and may inform drug development efforts.
PathAI is also working with academic institutions, biopharma companies and CROs to advance precision medicine. The company’s Early Access Program is made up of 13 academic medical centers, health systems, reference laboratories, and independent pathology organizations from across the country. The program’s goal is to gather real-world evidence on the use of digital pathology tools to advance precision medicine for the benefit of patients all over the world. PathAI’s Early Access Program may also provide valuable insights for the development of AI-driven research tools and algorithms that can aid in drug development efforts.
Filed Under: Drug Discovery and Development
Tell Us What You Think!
You must be logged in to post a comment.